CYBN Logo

Cybin Inc. (CYBN) Stock Forecast & Price Prediction

Live CYBN Stock Price & Analysis

Home โ€บ Stocks โ€บ Canada | NYSE | Healthcare | Biotechnology

$9.00

-0.41 (-4.36%)

12 Month Price Forecast For CYBN

$9.00
Current Price
$187.40M
Market Cap
5 Ratings
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to CYBN Price Forecasts

+2,017.1%
To High Target of $190.54
+993.2%
To Median Target of $98.39
+173.1%
To Low Target of $24.58

CYBN Price Momentum

-9.2%
1 Week Change
-5.9%
1 Month Change
-28.7%
1 Year Change
+2.0%
Year-to-Date Change
-54.6%
From 52W High of $19.84
+38.5%
From 52W Low of $6.50

๐Ÿค” Considering Cybin (CYBN)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 8, 2025 10:03 AM UTC

CYBN Analyst Ratings & Price Targets

Based on our analysis of 7 Wall Street analysts, CYBN has a consensus that is bullish. The median price target is $98.39, with forecasts ranging from $24.58 to $190.54. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With CYBN currently trading at $9.00, the median price forecast suggests a 993.2% upside. The most optimistic forecast comes from at , projecting a 2,017.1% upside, while at provides the most conservative target, suggesting a 173.1% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CYBN Analyst Consensus

5
Buy
0
Hold
0
Sell

CYBN Price Target Range

Low
$24.58
Average
$98.39
High
$190.54
Current: $9.00

Latest CYBN Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CYBN.

Date Firm Analyst Rating Change Price Target
Jan 27, 2025 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $190.00
Nov 19, 2024 Canaccord Genuity Sumant Kulkarni Buy Maintains $86.00
Nov 19, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $190.00
Nov 18, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $190.00
Nov 14, 2024 Canaccord Genuity Sumant Kulkarni Buy Maintains $86.00
Sep 23, 2024 Canaccord Genuity Sumant Kulkarni Buy Maintains $96.00
Aug 23, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $5.00
Jul 31, 2024 Cantor Fitzgerald Charles Duncan Overweight Reiterates $0.00
Jul 31, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $5.00
Jun 21, 2024 Cantor Fitzgerald Charles Duncan Overweight Reiterates $0.00
May 16, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $5.00
Mar 13, 2024 HC Wainwright & Co. Patrick Trucchio Buy Maintains $5.00
Feb 15, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $5.00
Nov 17, 2023 HC Wainwright & Co. Patrick Trucchio Buy Maintains $5.00
Oct 31, 2023 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $10.00
Sep 1, 2023 Canaccord Genuity Sumant Kulkarni Buy Reiterates $5.00
Aug 30, 2023 Oppenheimer Francois Brisebois Outperform Reiterates $4.00
Aug 29, 2023 Cantor Fitzgerald Charles Duncan Overweight Reiterates $3.00
Aug 29, 2023 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $10.00
Aug 22, 2023 Cantor Fitzgerald Charles Duncan Overweight Reiterates $3.00

Stocks Similar to Cybin Inc.

The following stocks are similar to Cybin based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Cybin Inc. (CYBN) Financial Data

Cybin Inc. has a market capitalization of $187.40M with a P/E ratio of -0.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -49.1%.

Valuation Metrics

Market Cap $187.40M
Enterprise Value $28.53M
P/E Ratio -0.9x
PEG Ratio -1.9x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +100.0%
Current Ratio 41.7x
Debt/Equity 0.1x
ROE -49.1%
ROA -32.7%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Cybin Inc. logo

Cybin Inc. (CYBN) Company Overview

About Cybin Inc.

What They Do

Develops psychedelic-based therapeutics for mental health.

Business Model

Cybin Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of psychedelic-based therapeutics. It generates revenue by advancing its drug candidates through clinical trials and forming strategic partnerships for research and development, as well as potential commercialization of its therapies.

Additional Information

The company's pipeline includes several compounds in various stages of clinical trials aimed at treating conditions such as major depressive disorder and generalized anxiety disorders. Additionally, Cybin has established collaborations with organizations like TMS Neurohealth Centers and Kernel to enhance its research capabilities and develop innovative treatment solutions. Headquartered in Toronto, Canada, Cybin is positioned at the forefront of the emerging psychedelic therapy market.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

50

CEO

Country

Canada

IPO Year

2019

Cybin Inc. (CYBN) Latest News & Analysis

CYBN stock latest news image
Quick Summary

Wall Street analysts' price targets suggest a potential upside of 952.2% for Cybin Inc. (CYBN), supported by positive earnings estimate revisions.

Why It Matters

A 952.2% price target upside for Cybin Inc. suggests significant growth potential, while positive earnings revisions may enhance investor confidence and drive stock performance.

Source: Zacks Investment Research
Market Sentiment: Positive
CYBN stock latest news image
Quick Summary

Cybin Inc. has launched a strategic partnership with Segal Trials to advance its Phase 3 program for CYB003, aimed at treating Major Depressive Disorder.

Why It Matters

Cybin's partnership with Segal Trials enhances its Phase 3 program for CYB003, signaling progress in mental healthcare innovations, potentially boosting investor confidence and stock performance.

Source: Business Wire
Market Sentiment: Neutral
CYBN stock latest news image
Quick Summary

Cybin Inc. (NYSE American: CYBN) reported significant progress in 2024 towards revolutionizing mental healthcare and outlined upcoming milestones for 2025.

Why It Matters

Cybin's advancements in neuropsychiatry and its commitment to innovative treatments could enhance its market position, potentially influencing stock performance and investor sentiment.

Source: Business Wire
Market Sentiment: Neutral
CYBN stock latest news image
Quick Summary

Cybin Inc. CEO Doug Drysdale will participate in a virtual fireside chat at the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025.

Why It Matters

Cybin's CEO participation in a healthcare summit highlights its commitment to innovation in mental health, potentially influencing investor confidence and interest in its growth prospects.

Source: Business Wire
Market Sentiment: Neutral
CYBN stock latest news image
Quick Summary

Cybin Inc. will present two posters at the ACNP Annual Meeting from December 8-11, 2024, showcasing 12-month efficacy results for its innovative mental healthcare treatments.

Why It Matters

Cybin's presentation at a key conference highlights progress in mental health treatments, potentially boosting investor confidence and interest in its innovative therapies.

Source: Business Wire
Market Sentiment: Neutral
CYBN stock latest news image
Quick Summary

Cybin Inc. (NYSE: CYBN) executives will join the Water Tower Research Fireside Chat Series, highlighting their focus on innovative mental healthcare solutions.

Why It Matters

Cybin's participation in the Fireside Chat Series signals transparency and engagement, potentially boosting investor confidence and highlighting its commitment to mental healthcare innovation.

Source: Business Wire
Market Sentiment: Neutral

Frequently Asked Questions About CYBN Stock

What is Cybin Inc.'s (CYBN) stock forecast for 2025?

Based on our analysis of 7 Wall Street analysts, Cybin Inc. (CYBN) has a median price target of $98.39. The highest price target is $190.54 and the lowest is $24.58.

Is CYBN stock a good investment in 2025?

According to current analyst ratings, CYBN has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.00. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CYBN stock?

Wall Street analysts predict CYBN stock could reach $98.39 in the next 12 months. This represents a 993.2% increase from the current price of $9.00. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Cybin Inc.'s business model?

Cybin Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of psychedelic-based therapeutics. It generates revenue by advancing its drug candidates through clinical trials and forming strategic partnerships for research and development, as well as potential commercialization of its therapies.

What is the highest forecasted price for CYBN Cybin Inc.?

The highest price target for CYBN is $190.54 from at , which represents a 2,017.1% increase from the current price of $9.00.

What is the lowest forecasted price for CYBN Cybin Inc.?

The lowest price target for CYBN is $24.58 from at , which represents a 173.1% increase from the current price of $9.00.

What is the overall CYBN consensus from analysts for Cybin Inc.?

The overall analyst consensus for CYBN is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $98.39.

How accurate are CYBN stock price projections?

Stock price projections, including those for Cybin Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.